KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Treasury Shares (2020 - 2025)

Castle Biosciences' Treasury Shares history spans 6 years, with the latest figure at $3.4 million for Q4 2025.

  • For Q4 2025, Treasury Shares rose 6.24% year-over-year to $3.4 million; the TTM value through Dec 2025 reached $3.4 million, up 6.24%, while the annual FY2025 figure was $3.4 million, 6.24% up from the prior year.
  • Treasury Shares for Q4 2025 was $3.4 million at Castle Biosciences, up from $350144.0 in the prior quarter.
  • Across five years, Treasury Shares topped out at $3.5 million in Q4 2022 and bottomed at $196033.0 in Q4 2023.
  • The 5-year median for Treasury Shares is $2.1 million (2021), against an average of $1.9 million.
  • The largest annual shift saw Treasury Shares crashed 94.36% in 2023 before it soared 1530.45% in 2024.
  • A 5-year view of Treasury Shares shows it stood at $1.1 million in 2021, then skyrocketed by 231.18% to $3.5 million in 2022, then crashed by 94.36% to $196033.0 in 2023, then skyrocketed by 1530.45% to $3.2 million in 2024, then rose by 6.24% to $3.4 million in 2025.
  • Per Business Quant, the three most recent readings for CSTL's Treasury Shares are $3.4 million (Q4 2025), $350144.0 (Q3 2025), and $3.2 million (Q4 2024).